The PreDiCT-TB consortium and the Critical Path to TB Drug Regimens (CPTR) have signed a memorandum of understanding to coordinate the work in developing new and effective treatment regimens for tuberculosis (TB). This was facilitated by two of the world’s leading organizations advancing scientific breakthroughs that help accelerate drug approvals, the Innovative Medicines Initiative (IMI) and Critical Path Institute (C-Path).
TB remains one of the leading causes of death worldwide. Nearly nine million new cases of TB and 1.4 million deaths are reported each year. Standard TB treatment takes months with a multi-drug regimen, while treating drug-resistant strains—which are on the rise globally—may take two years.
PreDiCT-TB is a public-private partnership funded by the EU Innovative Medicines Initiative, comprising three major pharmaceutical partners (GSK, Sanofi, and Janssen), two biotechnology firms (ZF Screens and Microsens Medtech) and fifteen academic partners headed by the University of Liverpool. The multidisciplinary consortium brings together experts in microbiology, pharmacology, engineering, mathematical modelling, and clinical trials to create a new integrated framework for TB drug development, making optimal use of preclinical information to design the most efficient clinical trials.